


October
3-5
2019

Hotel Garden
Siena

PROGRAM



III SIENA THINK TANK

A VISION OF I-O CALL FOR ACTIONS

Promoted by the NIBIT Foundation in collaboration with the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council



FONDAZIONE
NIBIT
ONLUS

Network italiano per la Ricerca dei Tumori



PARKER
INSTITUTE
FOR CANCER
IMMUNOTHERAPY

WIC
World Immunotherapy Council



www.thinktanksiena.com

A VISION OF I-O

Thursday
October
3rd
2019

18:00

Welcome to the Ill Siena I-O Think Tank

Michele Maio (Siena, Italy), Bernie Fox (Portland, USA) and Ramy Ibrahim (San Francisco, USA)

18:15 - 20:00

Tuning-up for the THINK TANK:
Different career trajectories
within the I-O community

Interviewer

Ramy Ibrahim (San Francisco, USA)

Academia

Soldano Ferrone (Boston, USA)

Academia

Michele Maio (Siena, Italy)

Analyst/Investment

Asthika Goonewardene (New York, USA)

Pharma and Biotech

Kimberly Plessala (San Francisco, USA)

The Academia/Industry Venture


Bernie Fox (Portland, USA)

Scientific Journalist

Daniela Minerva (Milan, Italy)

20:30

Wine & cheese



Friday
**October
4th
2019**

08:45 - 09:00 **Welcome addresses**

Michele Maio (Siena, Italy), Bernie Fox (Portland, USA)
and Ramy Ibrahim (San Francisco, USA)

SESSION 1 | Epigenetic immune modeling/ re-modeling

**Chairs: Michele Maio (Siena, Italy), Harold Keer (San Francisco, USA)
and Barbara Seliger (Halle, Germany)**

09:00 **Focus on the topic** - Michele Maio (Siena, Italy)

09:10 **Tumor microenvironment** - Andrea Anichini (Milan, Italy)

09:40 **Immune implications with HMA treatment in hematological malignancies**
Harold Keer (San Francisco, USA)

10:10 **The epigenetic plus I-0 strategy goes to the clinic: the NIBIT Foundation studies**
Anna Maria Di Giacomo (Siena, Italy)

10:40 **Conclusions and call for actions** - Chair and Co-Chairs

11:10 - 11:40 *Coffee break*

SESSION 2 | Early phase development of novel targets

Chairs: Wolf Hervé Fridman (Paris, France) and Roberto Camerini (Lugano, Switzerland)

11:40 **Demonstrating monotherapy activity in a Phase 1 trial: what constitutes activity**
Kevin Heller (Washington DC, USA)

12:05 **The window of opportunity strategy** - Michael Lahn (Geneva, Switzerland)

12:30 **ICOS: The INDUCE-1 study** - Marc Ballas (Philadelphia, USA)

12:55 **Conclusions and call for actions** - Chair and Co-Chair

13:10 - 14:30 *Lunch break*

SESSION 3 | Cellular immunotherapy


Chairs: Ramy Ibrahim (San Francisco, USA), Dominik Ruettinger (Munich, Germany) and Paola Nisticò (Rome, Italy)

- 14:30 **Focus on the topic** - Ramy Ibrahim (San Francisco, USA)
- 14:40 **Therapeutic vaccines** - Samir Khleif (Washington DC, USA)
- 15:10 **CAR-T cells** - Franco Locatelli (Rome, Italy)
- 15:40 **Virus-specific T cells** - John Connolly (Singapore)
- 16:10 **Induced pluripotent stem cells** - Mark Kotter (Cambridge, UK)
- 16:40 **Conclusions and call for actions** - Chair and Co-Chairs
- 17:10 - 17:30 *Tea break*

SESSION 4 | Young Investigators: proposals and opportunities

Chairs: Soldano Ferrone (Boston, USA), Catherine Sautès Fridman (Paris, France) and Patrick Garcia (Darmstadt, Germany)

- 17:30 **The Mediterranean task force for Cancer Control: an international partner for the NIBIT Foundation Think Tank** - Pier Giorgio Natali (Siena, Italy)
- 17:45 **Four selected “Young Investigator” proposals** - To be announced
- 18:45 **Conclusions and call for actions** - Chair and Co-Chairs
- 20:30 *Dinner at “Loggia dei Nove”, downtown Siena*



Saturday
**October
5th
2019**

SESSION 5 | New technologies and novel computational approaches

Chairs: Nikesh Kotecha (San Francisco, USA) and Zlatko Trajanoski (Innsbruck, Austria)

- 09:00 **Pharmacogenomics and predicting drug combinations**
Michael Menden (Munich, Germany)
- 09:25 **High-dimensional multi-omics analysis of clinical samples**
Pier Federico Gherardini (San Francisco, USA)
- 09:50 **Deep proteomic profiling of CD4+ and CD8+ T cell depleted syngeneic tumor models under PD-1 treatment** - Hoachen Yu (Schlieren, Switzerland)
- 10:15 **Conclusions and call for actions** - Chair and Co-Chair
- 10:30 - 11:00 *Coffee break*

SESSION 6 | Focus on glioblastoma: the path ahead

Chairs: Alexander Eggermont (Paris, France) and Joseph Eid (Lawrenceville, USA)

- 11:00 **Immunobiology and genetics** - Michele Ceccarelli (Redwood City, USA)
- 11:25 **Clinical results and opportunities** - Robert Prins (Los Angeles, USA)
- 11:50 **Deeper molecular analysis of neoadjuvant GBM trial**
Nicholas L. Bayless (San Francisco, USA)
- 12:15 **Conclusions and call for actions** - Chair and Co-Chair

SESSION 7 | Focus on mesothelioma: the path ahead

Chairs: Lucio Crinò (Meldola, Italy) and Olivier Provendier (Paris, France)

- 12:30 **Immunobiology** - Robin Cornelissen (Rotterdam, The Netherlands)
- 12:55 **Clinical results and opportunities** - Luana Calabrò (Siena, Italy)
- 13:20 **Spatial expression profiling of mesothelioma** - Bernie Fox (Portland, USA)
- 13:45 **Conclusions and call for actions** - Chair and Co-Chair


THE IV SIENA I-O THINK TANK 2020

OCTOBER 8-10, 2020

HOTEL GARDEN SIENA

**SEE YOU
NEXT YEAR!**





INTERNATIONAL SCIENTIFIC COMMITTEE

- Andrea Anichini** - Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)
Alexander Eggermont - Goustave Roussy, Paris-Sud University, Paris (France)
Bernie Fox - Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland (USA)
Wolf Hervé Fridman - Centre de Recherche des Cordeliers, Paris (France)
Ramy Ibrahim - Parker Institute for Cancer Immunotherapy, San Francisco (USA)
Michele Maio - Center for Immuno-Oncology, Siena (Italy)
Pier Giorgio Natali - NIBIT Foundation ONLUS, Siena (Italy)

LOCAL SCIENTIFIC COMMITTEE

- Anna Maria Di Giacomo** - Center for Immuno-Oncology, Siena (Italy)
Alessia Covre - Center for Immuno-Oncology, Siena (Italy)
Luana Calabrò - Center for Immuno-Oncology, Siena (Italy)

FACULTY

- Andrea Anichini** - Fondazione IRCCS Istituto Nazionale Tumori, Milan (Italy)
Marc Ballas - GSK, Philadelphia (USA)
Nicholas L. Bayless - Parker Institute for Cancer Immunotherapy, San Francisco (USA)
Luana Calabrò - Center for Immuno-Oncology, Siena (Italy)
Roberto Camerini - Cosmo, Lugano (Switzerland)
Michele Ceccarelli - AbbVie Biotherapeutics, Redwood City (USA)
John Connolly - Tessa Therapeutics Ltd. (Singapore)
Robin Cornelissen - Erasmus MC, Rotterdam (The Netherlands)
Lucio Crinò - IRST, Meldola (Italy)
Anna Maria Di Giacomo - Center for Immuno-Oncology, Siena (Italy)
Alexander Eggermont - Goustave Roussy, Paris-Sud University, Paris (France)
Joseph Eid - Bristol-Myers Squibb, Lawrenceville (USA)
Soldano Ferrone - Harvard Medical School, Boston (USA)
Bernie Fox - Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland (USA)

A VISION OF I-O

Catherine Sautès Fridman - Centre de Recherche des Cordeliers, Paris (France)
Wolf Hervé Fridman - Centre de Recherche des Cordeliers, Paris (France)
Patrick Garcia - Merck KGaA, Darmstadt (Germany)
Pier Federico Gherardini - Parker Institute for Cancer Immunotherapy, San Francisco (USA)
Asthika Goonewardene - SunTrust Robinson Humphrey, New York (USA)
Kevin Heller - NextCure, Washington DC (USA)
Ramy Ibrahim - Parker Institute for Cancer Immunotherapy, San Francisco (USA)
Harold Keer - Astex Pharmaceuticals Inc., San Francisco (USA)
Samir Khleif - Georgetown University, Washington DC (USA)
Nikesh Kotecha - Parker Institute for Cancer Immunotherapy, San Francisco (USA)
Mark Kotter - Elpis BioMed Ltd., Cambridge (UK)
Michael Lahn - iOnctura SA, Geneva (Switzerland)
Franco Locatelli - IRCCS Ospedale Pediatrico Bambino Gesù, Rome (Italy)
Michele Maio - Center for Immuno-Oncology, Siena (Italy)
Michael Menden - Institute of Computational Biology, Munich (Germany)
Daniela Minerva - Live, Milan (Italy)
Pier Giorgio Natali - NIBIT Foundation ONLUS, Siena (Italy)
Paola Nisticò - Regina Elena National Institute for Cancer Treatment and Research, Rome (Italy)
Kimberly Plessala - Parker Institute for Cancer Immunotherapy, San Francisco (USA)
Robert Prins - California University, Los Angeles (USA)
Oliver Provendier - Pierre Fabre Médicament, Paris (France)
Dominik Ruettinger - Roche, Munich (Germany)
Barbara Seliger - Institute for Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Germany)
Zlatko Trajanoski - Medical University, Innsbruck (Austria)
Haochen Yu - Biognosys Technology, Schlieren (Switzerland)

INVITEES FACULTY

Massimo Aglietta - Oncologia Medica Università degli Studi di Torino, Turin (Italy)
Gregorio Aversa - Abimmune Technologies, Vancouver (Canada)
Daniele Banfi - Fondazione Veronesi, Milan (Italy)
Jennifer Burbea - NIBIT Foundation ONLUS, Siena (Italy)
Elisabetta Calabrese - Bristol-Myers Squibb, Rome (Italy)
Ennio Carbone - Università Magna Graecia, Catanzaro (Italy)
Elisa Dapretto - Pierre Fabre Pharma, Milan (Italy)
Elisabetta Ferretti - La Sapienza University, Rome (Italy)
Massimo Guidoboni - IRCCS IRST, Meldola (Italy)
Katia Lorizzo - MSD, Milan (Italy)
Salvatore Muscherà - Eli Lilly, Florence (Italy)
Cosimo Paga - Bristol-Myers Squibb, Rome (Italy)
Giuseppe Palmieri - Institute of Biomolecular Chemistry-CNR, Sassari (Italy)
Ulrich Pfeffer - San Martino Hospital, National Institute for Cancer Research, Genoa (Italy)
Maria Sofia Rosati - GSK, Verona (Italy)

PROMOTED BY



PLATINUM SPONSOR



Bristol-Myers Squibb

GOLD SPONSOR



SILVER SPONSORS



BRONZE SPONSORS




SUPPORTED BY



III SIENA THINK TANK

ENDORSERS



Meeting Venue

Hotel Garden
Via Custoza 2
Siena, Italy

Scientific Secretariat



NIBIT Foundation ONLUS

Phone: +39 3490582533

Fax +39 0577 586303

segreteria@fondazionenibit.org

www.fondazionenibit.org

www.thinktank-nibitfoundation.org

Organizing Secretariat

VYVAMED

VyvaMed Srl

Via Spadolini 7 - Centro Leoni, Palazzo B - 20141 Milano

Phone: +39 02 5416951 - Fax +39 02 54169554